Simoa SARS-CoV-2 N Protein Antigen Test is first antigen test validated to detect all Variants of Concern currently designated by CDC, including Delta variant, and first authorized for use in saliva samples EUA label expansion demonstrates additional evidence showing potential for Simoa technology across range of clinical tests, including less-invasive testing BILLERICA, Mass., September 13,... Read more
Infectious Disease Technology Antibody test available on Simoa HD-X Analyzer® detects and quantitates IgG antibodies to SARS-CoV-2 in serum or EDTA plasma BILLERICA, Mass., December 28, 2020 – Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use... Read more
NOVEMBER 04, 2019 BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix’ proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will allow Siemens... Read more
BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the closing of its previously announced underwritten public offering of 2,732,673 shares of its common stock at a public offering price of $25.25 per share, including 356,435 shares sold pursuant to the... Read more
AUGUST 09, 2019 BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,376,238 shares of its common stock at a public offering price of $25.25 per share. All of the shares... Read more
AUGUST 08, 2019 August 07, 2019 04:23 PM Eastern Daylight Time BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. In connection with the... Read more
ADDS BROAD-BASED EXPERIENCE GROWING AND SCALING MULTI-BILLION-DOLLAR INTERNATIONAL COMPANIES | JULY 26, 2019 Billerica, Mass. – July 26, 2019 — Quanterix Corporation(NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has further strengthened its Board of Directors with the election of Sarah Hlavinka by the Company’s shareholders.Hlavinka succeeds Douglas G. Cole, M.D., who did not stand for re-election.... Read more
JULY 23, 2019 MINNEAPOLIS, July 23, 2019 /PRNewswire/ — Uman Diagnostics, now part of Quanterix, and Bio-Techne announced today a strategic License and Supply Agreement for the antibodies used in the quantification of neurofilament light (Nf-L) on the ProteinSimple™-branded Ella™ immunoassay platform. Under the terms of the agreement, Uman Diagnostics will supply Nf-L antibodies to Bio-Techne... Read more
JUNE 28, 2019 June 28, 2019 12:15 PM Eastern Daylight Time BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been recognized with the Entrepreneur Of The... Read more
JUNE 26, 2019 Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier Positions Quanterix to capitalize on significant growth opportunities with Nf-L applications in Alzheimer’s Disease, Multiple Sclerosis, and other neurodegenerative conditions Provides expected 200 bps of annualized company gross margin improvement, before impact of purchase price accounting, and expected to... Read more